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1070-58 Ramipril Is Cost-Effective in Preventing Cardiovascular 
Events in Patients With Diabetes Mellitus 
Rita Ganaulv , Trivandrum V. Parasuraman, Wyeth Research, St. Davids, PA 
Background: Heart Outcomes Prevention Evaluation (HOPE) study and MICRO-HOPE 
sub-study showed significant mortality and morbidity benefits associated with the angio- 
tensin converting enzyme inhibitor, ramipril (AltaceTM), in the treatment of patients at 
high-risk for cardiovascular (CV) events. MICRO-HOPE, a randomized, placebo con- 
trolled study of ramipril, followed 3,577 high-risk diabetic patients. The primary outcome, 
a composite of myocardial infarction (Ml), stroke and CV death, was reduced from 19.6% 
in placebo to 15.3% in ramipril (relative risk reduction, 25%; p = OSX@l). Cardiac mortal- 
ity was also significantly reduced from 9.7% in placebo to 6.2% in ramipril (relative risk 
reduction, 37%; p = O.ooOl). With increasing cost containment pressures, there is a need 
to establish the cost-effectiveness of ramipril therapy in high-risk diabetic patients. 
Methods: A retrospective decision analysis was conducted to estimate cost-effectiveness 
ratio from a payer perspective using direct medical costs of clinical events from the litera- 
ture and efficacy data from the MICRO-HOPE study. Within-trial cost-effectiveness was 
estimated by the ratio of incremental expected cost of ramipril therapy to life years 
gained (LYG). LYG is the product of the ‘within-trial” difference in cardiac mortality rates 
and study duration. Efficacy data from MICRO-HOPE was used to populate the probabil- 
ities and compute the associated expected cost of fatal and non-fatal MI, stroke, cardiac 
mortality and other events. Drug costs were based on 1999 Red Book average wholesale 
price. All costs were discounted at 3% per year. 
Results: Over the trial period of 4 years, the base case discounted cost of ramipril ther- 
apy was $2,463 compared to $1.609 in placebo. This translates to a net incremental cost 
of $654 per patient on ramipril therapy. With a 3.5% absolute risk reduction in cardiac 
mortality, the incremental “within trial” cost per LYG was $4,671. Sensitivity analysis indi- 
cated that these estimates ranged from a cost per LYG of $4,464 to $4,764. 
Conclusion: Based on our estimates on cost per LYG we conclude that ramipril is cost- 
effective in preventing CV events in patients with Diabetes Mellitus. 
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1095-51 The Cyclooxygenase-2 Specific Inhibitor Valdecoxib Is 
Not Associated With an Increased Risk of 
Cardiovascular Thrombotlc Events in Arthritis Patients 
William B. White, Kenneth M. Verburg, Andrew Whelton, University of Connecticut, 
Farmington, CT, Pharmacia Corporation, Skokie, IL 
Background: There are concerns that the risk of serious thrombotic events may be higher 
with cyclooxygenase 
(COX).2 specific inhibitors than nonselective nonsteroidal anti-inflammatory drugs 
(NSAIDs). Valdecoxib. a new COX-2 specific inhibitor is approved in the US for treating 
osteoarthritis/rheumatoid arthritis (OAIRA; 10 mg qd) and primary dysmenorrhea (20 mg 
bid, PRN). Methods: The Incidence of serious thrombotic events (cardiac, cerebrovascu- 
lar and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled 
valdecoxib (lo-60 mg dally), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 600 
mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized. 6 to 52-week 
OAfRA trials. The incidence of events was determined in all patients (n = 7934), and 
aspirin (ASA; up to 325 mglday) and non-ASA users. Results: Crude and exposure- 
adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and pla- 
cebo (Table). The risk of serious thrombotic events was similar for each valdecoxib dos- 
age. Thrombotic risk was consistently higher for ASA-users than non-users (placebo 
1.4% vs 0%; valdecoxib 1.7% vs 0.2%; NSAlDs 1.9% YS 0.5%). The rates of events in 
ASA-users were similar for each treatment. Conclusion: Shorl and intermediate-term 
treatment with therapeutic and supratherapeutic valdacoxib doses was not associated 
with an increased incidence of thrombotic events relative to nonselective NSAlDs or pla- 
cebo in OAIRA Datients in controlled clinical trials. 
Number of 
Patients 
Total Exposure 
(patient-years) 
SWiOUS 
Thrombotic 
Events 
Any Event7 
Myocardial 
Infarction 
Myocardial lschemia 
and Unstable Angina 
Cerebrovascular 
Disorder 
Peripheral 
Arterial 
lschemia 
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Placebo Valdecoxib NSAlDs 
1142 4531 
161.1 1340.5 
” (%) IR’ ” (%) 
2 (0.2) 1.2 17 (0.4) 
1 (<O.l) 0.6 6 (0.1) 
0 (0.0) 0.0 1 (cO.1) 
1 (cO.1) 0.6 6 (0.2) 
0 (0.0) 0.0 1 (<O.l) 
2261 
655.7 
IR’ n (%) IR 
1.3 13 (0.6) 2.0 
0.4 7 (0.3) 1.1 
co.1 2 (<O.l) 0.3 
0.6 5 (0.2) 0.6 
<O.l 0 (0.0) 0.0 
‘IR= incidence rate, events par 100 patient-years. tA patient with more than one 
thrombotic event is counted only once in this overall incidence. No significant 
differences between groups. Sponsored by Pharmacia Corporation and Pfizer Inc 
1095-52 Increase in Risk Associated With a Statin Therapeutic 
Interchange Policy 
Peter Dumq Ltna Saad, Alison Tran. Anna Vichiendilokkul, Wayne State University, 
Detroit, MI, Harper University Hospital, Detroit, MI 
Therapeutic interchange (TI) is a common formulary management approach. It involves 
the substitution of one drug for another drug in its class at an equipotent dose. A TI policy 
for the statin class was implemented at our institution, with the preferred statin bemg sim- 
vastatin (SMV). We conducted the current study to assess the impact of this TI policy on 
the likelihood of drug interactions with SMV. 
Methods: Pharmacy records were reviewed for all inpatients prescribed a statin during 
the 3 months before and after the TI process was implemented. Patients who received 
any statin in combination wth an agent to produce a moderate or severe drug interaction 
had their inpatient medical chart reviewed. Drug interactions were classified as moderate 
and sevare, according to pharmacokinetic studies, reports of muscle-related toxicity, and 
FDA product labeling. Data was collected on interacting medications, statin dose, co- 
morbid conditions, muscle-related toxicity. 
Results: 1472 hospital admissions were evaluated in this study. Of the 744 patients 
admitted after implementation of the TI policy, 126 were exposed to moderate or severe 
drug interactions, compared to 59 exposures among the 726 patients that did not experi- 
ence TI (p-z 0.001). The average length of exposure to the interacting agent was 3 days. 
Twenty-nine patients in the post-T1 group were discharged on a regimen that included a 
moderate or severe drug interaction, compared to 17 patients in the pre-TI group (p= 
0.27) 
Conclusions: A TI program with SMV as the preferred agent resulted in doubling of expo- 
sure to moderate or severe drug interactions during hospitalization. This increase 
occured despite significant pharmacy and medical education regarding drug interactions 
with simvastatin. The increase in in-hospital drug interactions did not result in an increase 
in drug-interactions with discharge medications. We conclude that an inpatient TI pro- 
gram ,with SMV as the agent of choice, increases patients’ exposure to significant drug 
interactions. Institutions should carefully consider patient safety issues before embarking 
on such a program, as well as develop appropriate safety mechanisms to minlmize drug 
interactions. 
1095-53 Clinical Trials of Smoking Cessation Aids: A Meta- 
Analysis 
Jason R. Ludviq, Mark J. Eisenberg, Jewish General Hospital, Montreal, PQ, Canada 
Background: Although multiple clinical trials have examined smoking cessation aids, a 
systematic review of the efficacy of smoking cessation aids has yet to be performed. 
Methods: Forty-one clinical trials examining various smoking cessation aids were identi- 
fied. Eleven trials examined the nicotine patch (w4375); 11 trials nicottne gum (w3624); 
5 trials nkxtine inhaler (n=2752); 6 trials bupropion (n=4251); and 6 clinical trials behav- 
ioral therapy (n=ZlOO). Results: Each smoking cessation aid was associated with an 
absolute and relative increase in smoking abstinence rates compared wth placebo at 
both 6 and 12 months. Absolute increases in smoking abstinence range from 6.9% 
(behavioral therapy) to 13.2% (ncotine inhaler) at 6 months and from 5.2% (nicotine 
patch) to 11.6% (bupropion) at 12 months. Relative increases m smoking abstinence 
range from 19.6% (behavioral therapy) to 131% (nicotine Inhaler) at 6 months and from 
44.1% (behavioral therapy) to 167% (nicotine inhaler) at 12 months. Despite increases in 
smoking abstinence rates of over 10% for most smokmg cessation aids when compared 
with placebo, overall smoking relapse rates are still 70%-60%. 
Conclusion: Smoking cessation aids effect an approximate 10% increase in smoking 
abstinence at 6 and12 months compared with placebo. Although there is a clincally and 
statistically significant Increase in abstinence with smoking cessation atds, overall absti- 
nence rates are still very low. 
526A ABSTRACTS - Special Topics JACC 
Pooled Analysis of 6 and I2 month Smoking Abstinence Rates 
Smoking Cessation Aid 
(dose) 
N Abstinence rates at N Abstinence rates at 
6 months (%) 12 months (%) 
Nicotine Patch 
(21 mg/ day) 
Nicotine Chewing Gum (2 
mg) 
Nicotine Inhaler 
(4 mg) 
265 9.6 19.0 171 7.7 
7 8 
192 19.1 31.7 169 12.9 
5 9 
137 10.1 23.3 137 6.9 
6 6 
Bupropion (300 mglday) 
287 16.1 29.5 137 21.0 
5 6 
Behavioral Therapy 
678 45.0 
Active Placebo 
53.9 122 27.8 
2 
Active 
12.9 
23.9 
18.4 
32.8 
36.9 
1095-54 Radioactive Cigarettes and Corporate Strategy in Light 
of Evidence Derived From Declassified Tobacco 
Industry Documents 
Hrayr S. Karaaueuzian, James Whiting, Cedars-Sinai Medical Center, David G&en 
School of Medicine at UCLA, Los Angeles, CA 
Background: The presence of significant radioactivity in tobacco smoke still remains 
unacknowledged by the tobacco industry (TI). Declassified TI documents shed light oh 
this policy of silence. Methods: All major online soumes of TI documents made available 
by the Minnesota State Attorney General were searched using the terms polonium; 
radioactivity. A total of 56 TI documents and 26 academic publications were selected and 
analyzed. Results: Two sources of tobacco radioactivity have been identified: atmo- 
spheric fallout and soil rich in artificfal fertilizer containing radium, polonium 21OP0, and 
lead 210Pb. The documents show that the TI knew of the presence of significant radioac- 
tivity in tobacco smoke since the early 1950s and had at its disposal all the technical 
means and exoertise needed to measure radioactivity in tobacco leaves and smoke 
(matn & side streams). TI scientists reported 21OPo content of 0.5 pCi/cigarette (i.e., 
0.037 disinteoration oer sec. dos) with 12% of radioactivitv in the main stream and 32% 
in the side stream of the smoke. Since the average daily intake of 2lOPo from food and 
beverages averages 0.1 dps, smokers of one pack (20 cigarettes) a day may intake twice 
the 21OPo activity as nonsmokers. Postmortem findings at the btfurcation of the lower 
lobes of the lung of smokers who died from lung cancer had at least 3 times higher 
PlOPo/g of lung tissue than nonsmokers. Filtering proved ineffective I” 2lOPo removal 
(~0.1%). The concern over the potential hazards of the ionizing alpha particles of 210Po 
in the smoke led TI executives to ban publishing all internal research findings oh radioac- 
tivity. The TI executives found established methods of PO removal using acid treatment 
of tobacco leaves unacceptable because acid media converts ntcotlne base to nicotine 
salt with diminished ability to penetrate the brain causing loss of instant ‘nicotine kick,” 
the documents show. Conclusions: The declassified TI documents show that the industry 
had scientifically accurate knowledge of the presence of radioacbvity in tobacco smoke 
that might promote lung cancer. Adding a warning label oh cigarette packages that 
acknowledges the presence of radioactivity in tobacco smoke seems appropriate. 
1095-55 Additive Benefits of Pravastatin and Aspirin to 
Decrease Risks of Cardiovascular Disease: 
Randomized and Observational Comparisons of 
Secondary Prevention Trials and Their Meta-Analysis 
Charles H. Hennekens, Frank M. Sacks, Andrew Tonkin, Wouter Jukema, Robert P. 
Byington. Bertram Pin, Donald A. Berry, Scott M. Berry, Neville F. Ford, Andrew J. 
Walker, Kannan Natarajan, Chen Sheng-Lln, Frederick T. Fiedorek, Rene Belder, 
University of Miami School of Medicine, Miami, FL 
Background: In randomized trials of secondary prevention, pravastatin and aspirin 
reduce risks of cardiovascular disease (CVD). Pravastatin has a predominantly anti- 
atherogenic effect and aspirin ah immediate anti-platelet effect. Whether they have addi- 
tive clinical benefits has hot been demonstrated. 
Methods: In five randomized thals with pravastatin (40mg), comprising 73,900 patient- 
years of observation, aspirin was also prescribed. We tested whether pravastatin and 
aspihn have additive benefits in the two large trials (LIPID and CARE). We also per- 
formed meta-analyses of these two trials as well as three far smaller angiographic trials 
with clinical endpoktts. In all analyses multivariate models were used to adjust for a large 
number of CVD risk factors 
Results: Both indiwdual trials as well as all meta-analyses demonstrated similar additive 
benefits of pravastatin and aspirin. In meta-analysis the relative risk reductions (RRRs) 
for fatal or non-fatal myocardial infarction (Ml) were 31% for pravastatin plus aspirin ver- 
sus aspirin alone and 26% for pravastatin plus aspirin vemus pravastatin alone. For 
ischemic stroke the corresponding RRRs were 29% and 31%. For the combined ehd- 
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point of coronary heart disease death, non-fatal MI, coronary artery bypass graft, percu- 
taneous transluminal coronary angioplasty or ischemic stroke the RRRs were 24% and 
13%. All RRRs were statistically significant. 
Conclusions: In randomized and observational comparisons of secondary prevention tri- 
als and their meta-analyses there were additive benefits of pravastatin and aspirin in 
reducing risks of CVD. The more widespread and appropriate use of both pravastatin 
and aspirin in secondary prevention of CVD will avoid large numbers of premature 
deaths. 
109556 Do Lipoprotein Subclass Tests Increase Treatment 
Rates in High-Risk Patients? 
Ronald M. Krauss, Soma S. Nag, Shiva G. Sajjan, Thomas W. Weiss, John Brunzell, 
Jere P. Segrest, Leona E. Markson, Charles M. Alexander, Merck & Co.. Inc.. West 
Point, PA 
Background: Although considerable debate surrounds the utility of lipoprotein subclass 
tests versus (vs.) traditional lipid profiles in clinical practice, we are not aware of studies 
on the impact of the availability of lipoprotein subclass tests oh the process of care. 
Methods: A 6.month. randomized, prospective multi-center study evaluated the impact of 
lipoprotein subclass tests (Atherotech) on lipid treatment rates and treatment intensity 
(defined by statin dose and/or the use of combination lipid therapy). Physicians were ran- 
domized to Group A (lipoprotein subclass test results available initially and at 6-months) 
or Group B (traditional lipid values initially and subclass results available only at 6 
months). Untreated, high-risk patients (N=2576) with coronary head disease (CHD), dia- 
betes, or other CHD-risk equivalents were enrolled. There were no protocol-dictated 
requirements for lipid testing or treatment. 
Results: There were 09 Group A vs. 97 Group B physicians. 45% of patients were in 
Group A while 55% were in Group B. Mean age of patients was 64.4 +/- 12.9 years 
(range 16-97) with 47.4% male and 52.6% female. 87.0% were Caucasian, 7.9% were 
African-American, and 5.1% were other raceslethnicities. The results below have not yet 
been adjusted for any differences in baseline charactehstcs. The group provided kpid 
subclass results (A) had higher initial and 6.month lipid treatment rates vs B (initial: 
56.2% “s 51.1%. p=O.Ol; follow-up: A=71.4% vs. B=62.1%; p&0001). In the subgroup 
of patients with baseline LDL >= 100 (ie, needed treatment) who were ieitlally untreated, 
baseline lipid profile values did hot differ significantly; follow-up lipid treatment rates dlf- 
fered significantly (Group A, 44.8% vs. Group B, 33.9% p=O.O02). 
Conclusion: These initial findings suggest that availability of lipoprotein subclass tests in 
these high-risk patients increases treatment rates. The relationship between risk factors 
and baseline characterisbcs. and differences in treatment rates and intensity remain to 
be evaluated. 
1095-57 Adherence to Chronic Therapy Among Patients Treated 
for Hypertension, Dyslipidemia, or Both 
J. Sanford Schwartz. Trent McLaughlin, Deborah Griffts, Amy Arnold, Daniel Pettitt, NDC 
Health, Phoenix, AZ, Pfizer, Inc., New York, NY 
Background: Persistent utilization of medicine in patients wtth concurrent hypertension 
and dyslipidemia is particularly important due to their elevated risk for coronary events. 
The objective of this analysis was to quantify medication adherence for patients receiving 
both an antihypertensive drug (AHD) and lipid regulating therapy (LRD). 
Methods: Retrospective claims analysts using data from several managed care organiza- 
tions (Source: PHARMetrics Integrated Outcomes Database). Patients receiving 
AHD+LRD during 1999-2000 & having -> 1 year of history following the index agent were 
included. Medication possession ratios (MPR) were calculated at P-month intervals to 
assess adherence for the AHD, LRD and AHD + LRD combined. An MPR ~0.80 was 
considered to be indicative of appropriate adherence to medication. 
Results: 5,341 patients were included in the analysis. Over one-thtrd of the sample was 
non-adherent by the end of the second month. While patients tended to be more adher- 
ent with one medication, less than half were adherent with both by month 2, and less 
than one third were adherent to both after one year. 
MPR >0.80 
AHD 
LRD 
AHD + LRD 
Month 
l-2 
66.7% * 
47.7% * 
37.7% 
Month 
3-4 
58.8% ’ 
44.9% * 
35.5% 
Month 
5-6 
56.9% * 
43.6% * 
34.0% 
Month 
7-a 
56.0% * 
42.4% * 
33.2% 
Month 
9-10 
54.7% ’ 
42.0% * 
32.9% 
* p<O.O5 versus AHD+LRD 
Conclusions: The addition of a second aaent is associated with a sianificant reduction I” 
adequate medication adherence, such that less than one third of all patients remain on 
both AHD and LRD by the end of the first year. 
1095-58 Can Changing Referral Patterns Based on ACCIAHA’ 
Practice Guidelines for Coronary Angiography Be 
Measured? Validation of a Decision Analysis Model of 
Test Appropriateness in Coronary Artery Disease 
Patients 
D. Douqlas Miller, Edward J. Dougherty, Debra E. Messinger, Saint Louis University, St. 
Louis, MO 
Background: Despite reimbursement constraints, U.S. coronary angiogtaphy (oath.) 
rates continue to rise. We developed and validated a decision analysis model based oh 
1999 ACC/AHA Guidelines for Coronary Angiography to assess the appropriateness of 
elective cath. to a large Florida health plan (AvMED). 
Methods: A retrospective comparison of Cath. rates & appropriateness was performed 
